Matthew Guo
Johns Hopkins Hospital(US)Sidney Kimmel Comprehensive Cancer Center(US)
Publications by Year
Research Areas
Platelet Disorders and Treatments, Cancer Immunotherapy and Biomarkers, Parathyroid Disorders and Treatments, Blood groups and transfusion, Sarcoma Diagnosis and Treatment
Most-Cited Works
- → Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial(2018)5,305 cited
- → Chemoradiotherapy of Locally Advanced Esophageal Cancer(1999)1,948 cited
- → Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial(2016)754 cited
- → Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial(2019)479 cited
- → Cinacalcet Hydrochloride Maintains Long-Term Normocalcemia in Patients with Primary Hyperparathyroidism(2005)463 cited
- → Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP(2008)432 cited
- → Cinacalcet HCl, an Oral Calcimimetic Agent for the Treatment of Secondary Hyperparathyroidism in Hemodialysis and Peritoneal Dialysis(2005)407 cited
- → The Calcimimetic Cinacalcet Normalizes Serum Calcium in Subjects with Primary Hyperparathyroidism(2003)249 cited
- → Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial(2017)181 cited
- → Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine(2017)163 cited